PLoS ONE (Jan 2018)

Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.

  • Aurore Goineau,
  • Loïc Campion,
  • Bénédicte d'Aillières,
  • Brigitte Vié,
  • Agnès Ghesquière,
  • Guillaume Béra,
  • Didier Jaffres,
  • Guy de Laroche,
  • Nicolas Magné,
  • Xavier Artignan,
  • Jérôme Chamois,
  • Philippe Bergerot,
  • Etienne Martin,
  • Gilles Créhange,
  • Elisabeth Deniaud-Alexandre,
  • Xavier Buthaud,
  • Yazid Belkacémi,
  • Mélanie Doré,
  • Laure de Decker,
  • Stéphane Supiot

DOI
https://doi.org/10.1371/journal.pone.0194173
Journal volume & issue
Vol. 13, no. 4
p. e0194173

Abstract

Read online

Radiotherapy can diminish quality of life (QoL) for prostate cancer patients. Our objective was to evaluate the effect of radiotherapy on QoL in men aged 75 years or older treated with radiotherapy for a localized prostate cancer, and to identify predictors of reduced QoL.We prospectively administered a battery of geriatric (MNA, GDS, Get up and Go Test, CIRS-G, ADL, IADL, MMSE), toxicity (IPSS; IIEF 5), and QoL (QLQ C30) screening tests in 100 elderly patients before and two months after prostate cancer radiotherapy (NCT 02876237). Patients ≥ 75 years undergoing radiotherapy with a curative intent for localized prostate cancer with or without androgen deprivation therapy (ADL) were eligible for study inclusion. Correlations between patient-assessed QoL and tumor characteristics, radiotherapy treatment or CGA parameters were sought using the Fisher or the Mann and Whitney tests. Changes in QoL parameters over time were analyzed using the Wilcoxon signed-rank test.At study entry, scores for IADL impairments were present in 51%, reduced autonomy in activities of daily living in 16%, cognitive impairment found in 20%, depression-related symptoms in 31%, and 66% of patients had significant co-morbidities. Eight percent were judged to be at risk of fall and 2% were found to be undernourished. Severely impaired (IPSS ≥ 20) urinary function was observed in 11.2% and 13.5% of patients before and two months after completion of radiotherapy respectively. Significantly decreased QoL (> 20 points) at two months after treatment was found in 13% of patients and a moderate but clinically relevant reduction (10 to 20 points) in 17% of patients. No tumor characteristic, treatment, or oncogeriatric parameter was predictive of reduced QoL following prostate cancer radiotherapy.Despite sometimes markedly diminished oncogeriatric parameters, prostate cancer radiotherapy was generally well tolerated in these elderly patients. We found no predictive factor to determine which patients would experience impaired quality of life following radiotherapy.